<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03717415</url>
  </required_header>
  <id_info>
    <org_study_id>DCC-2036-01-004</org_study_id>
    <nct_id>NCT03717415</nct_id>
  </id_info>
  <brief_title>A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors</brief_title>
  <official_title>An Open Label, Multicenter, Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Carboplatin to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced or Metastatic Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Deciphera Pharmaceuticals LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Deciphera Pharmaceuticals LLC</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label Phase 1b/2 multicenter study of rebastinib (DCC-2036) in combination
      with carboplatin designed to evaluate the safety, tolerability, and pharmacokinetics (PK) in
      patients with advanced or metastatic solid tumors.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (Part 1 and Part 2)</measure>
    <time_frame>Approximately 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective response rate (ORR) (Part 2)</measure>
    <time_frame>Approximately 24 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum observed concentration (Cmax) of rebastinib</measure>
    <time_frame>Cycle 1 Day 1, Cycle 2 Day 1 (each cycle is 21 days)</time_frame>
    <description>Measure the Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC) of rebastinib</measure>
    <time_frame>Cycle 1 Day 1, Cycle 2 Day 1 (each cycle is 21 days)</time_frame>
    <description>Measure the AUC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free-survival (PFS)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Measure of the time from Cycle 1 Day 1 to disease progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Measure of the time from Cycle 1 Day 1 to the first documentation of progressive disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Measure of time from first PR, CR to disease progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Measure of the interval between Cycle 1 Day 1 until date of death from any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">117</enrollment>
  <condition>Locally Advanced or Metastatic Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose comparison between 50 or 100 mg BID of rebastinib orally (PO) dosed in 21-day cycles in combination with carboplatin administered by IV infusion at either AUC5 or AUC6 once every 3 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose expansion in the following tumor types at the recommended Phase 2 dose (RP2D) of rebastinib in combination with carboplatin
Triple-negative breast cancer
Ovarian cancer
Mesothelioma</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rebastinib</intervention_name>
    <description>25 mg tablets or 75 mg tablets</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
    <other_name>DCC-2036</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>Carboplatin administered by IV infusion at AUC5 or AUC6</description>
    <arm_group_label>Part 1</arm_group_label>
    <arm_group_label>Part 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female patients ≥18 years of age at the time of informed consent.

          2. Part 1 (Dose Escalation). Histologically confirmed diagnosis of a locally advanced or
             metastatic solid tumor for which carboplatin is considered appropriate treatment.

          3. Part 2 (Dose Expansion)

               -  Previously treated, triple-negative breast cancer.

               -  Recurrent ovarian cancer.

               -  Histologically confirmed pleural or peritoneal malignant mesothelioma.

          4. ECOG performance status of ≤2.

          5. Able to provide an archival tumor tissue sample.

          6. Adequate organ function and bone marrow reserve.

          7. If a female of childbearing potential, must have a negative pregnancy test prior to
             enrollment.

          8. Patient must provide signed consent to participate in the study and is willing to
             comply with study-specific procedures.

        Exclusion Criteria:

          1. Received prior anticancer or other investigational therapy within 28 days or 5× the
             half-life (whichever is shorter) prior to the first dose.

          2. Not recovered from prior-treatment toxicities to Grade ≤1 or baseline.

          3. Peripheral neuropathy of any etiology &gt;Grade 1.

          4. Concurrent malignancy.

          5. Known active CNS metastases.

          6. Use of systemic corticosteroids.

          7. Known retinal neovascularization, macular edema or macular degeneration.

          8. History or presence of clinically relevant cardiovascular abnormalities.

          9. QTcF &gt;450 ms in males or &gt;470 ms in females.

         10. Left ventricular ejection fraction (LVEF) &lt;50% at screening.

         11. Arterial thrombotic or embolic events.

         12. Symptomatic venous thrombotic event.

         13. Active infection ≥Grade 3.

         14. Known HIV or HCV infection only if taking medications excluded per protocol, active
             HBV, or active HCV infection.

         15. Use of proton pump inhibitors.

         16. If female, the patient is pregnant or lactating.

         17. Major surgery 4 weeks prior to the first dose of study drug.

         18. Malabsorption syndrome or other illness which could affect oral absorption.

         19. Known allergy or hypersensitivity to any component of rebastinib or any of its
             excipients.

         20. Any other clinically significant comorbidities.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Trials</last_name>
    <phone>785-830-2100</phone>
    <email>clinicaltrials@deciphera.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Francisco (UCSF)</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Indiana University Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>NEXT Oncology</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>October 19, 2018</study_first_submitted>
  <study_first_submitted_qc>October 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">October 24, 2018</study_first_posted>
  <last_update_submitted>March 18, 2020</last_update_submitted>
  <last_update_submitted_qc>March 18, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>rebastinib</keyword>
  <keyword>breast cancer</keyword>
  <keyword>ovarian cancer</keyword>
  <keyword>mesothelioma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Rebastinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

